Elevance Health, Inc. (NYSE:ELV – Get Free Report) CFO Mark Kaye sold 10,584 shares of the company’s stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the sale, the chief financial officer owned 19,919 shares in the company, valued at $8,766,949.47. This represents a 34.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Elevance Health Trading Down 1.2%
Shares of NYSE ELV traded down $5.23 during midday trading on Friday, reaching $440.05. 1,144,956 shares of the stock were exchanged, compared to its average volume of 1,603,155. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $450.69. The stock has a 50 day moving average price of $407.53 and a 200-day moving average price of $390.54. The company has a market capitalization of $95.43 billion, a P/E ratio of 19.56, a P/E/G ratio of 2.12 and a beta of 0.70. The company has a current ratio of 1.47, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68.
Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. The company had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. Elevance Health’s revenue was up .7% on a year-over-year basis. During the same period in the previous year, the firm posted $6.03 EPS. Equities research analysts expect that Elevance Health, Inc. will post 29.00 earnings per share for the current fiscal year.
Elevance Health Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Friday, December 4th. Elevance Health’s payout ratio is presently 30.58%.
Analysts Set New Price Targets
ELV has been the subject of a number of research analyst reports. Leerink Partners increased their target price on shares of Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research report on Friday, July 17th. Raymond James Financial set a $450.00 target price on Elevance Health in a research report on Tuesday, July 7th. UBS Group increased their price target on shares of Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a research report on Thursday. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, Royal Bank Of Canada raised their target price on shares of Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $455.57.
Read Our Latest Stock Analysis on Elevance Health
Elevance Health News Summary
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
- Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
- Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
- Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
- Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
- Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
- Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
- Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Activest Wealth Management grew its stake in shares of Elevance Health by 146.2% in the third quarter. Activest Wealth Management now owns 64 shares of the company’s stock worth $25,000 after purchasing an additional 38 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Elevance Health during the second quarter valued at about $28,000. WealthCollab LLC lifted its holdings in Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after purchasing an additional 27 shares during the period. Elevation Wealth Partners LLC lifted its holdings in Elevance Health by 600.0% in the second quarter. Elevation Wealth Partners LLC now owns 105 shares of the company’s stock worth $41,000 after purchasing an additional 90 shares during the period. Finally, Tacita Capital Inc acquired a new stake in Elevance Health in the second quarter worth about $44,000. Institutional investors and hedge funds own 89.24% of the company’s stock.
About Elevance Health
Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.
Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.
Featured Articles
- Five stocks we like better than Elevance Health
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
